JP2023530235A - 個別化された処置方法のための製剤 - Google Patents

個別化された処置方法のための製剤 Download PDF

Info

Publication number
JP2023530235A
JP2023530235A JP2022575194A JP2022575194A JP2023530235A JP 2023530235 A JP2023530235 A JP 2023530235A JP 2022575194 A JP2022575194 A JP 2022575194A JP 2022575194 A JP2022575194 A JP 2022575194A JP 2023530235 A JP2023530235 A JP 2023530235A
Authority
JP
Japan
Prior art keywords
composition
salts
amino acid
compositions
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530235A5 (https=
Inventor
マドックス，オリバー・ディー・ケイ
Original Assignee
フェス・セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェス・セラピューティクス，インコーポレーテッド filed Critical フェス・セラピューティクス，インコーポレーテッド
Publication of JP2023530235A publication Critical patent/JP2023530235A/ja
Publication of JP2023530235A5 publication Critical patent/JP2023530235A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022575194A 2020-06-03 2021-06-02 個別化された処置方法のための製剤 Pending JP2023530235A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034137P 2020-06-03 2020-06-03
US63/034,137 2020-06-03
PCT/US2021/035476 WO2021247724A1 (en) 2020-06-03 2021-06-02 Formulations for personalized methods of treatment

Publications (2)

Publication Number Publication Date
JP2023530235A true JP2023530235A (ja) 2023-07-14
JP2023530235A5 JP2023530235A5 (https=) 2025-01-07

Family

ID=78829914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575194A Pending JP2023530235A (ja) 2020-06-03 2021-06-02 個別化された処置方法のための製剤

Country Status (7)

Country Link
US (2) US12220402B2 (https=)
EP (1) EP4161501A4 (https=)
JP (1) JP2023530235A (https=)
CN (2) CN116075238B (https=)
AU (1) AU2021283293B2 (https=)
CA (1) CA3181158A1 (https=)
WO (1) WO2021247724A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069462A (zh) 2016-02-23 2018-12-21 癌症研究科技有限公司 缺乏至少两种非必需氨基酸的膳食产品
JP2023530235A (ja) 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
CN114947139A (zh) * 2022-04-28 2022-08-30 成都尚医信息科技有限公司 一种影响肿瘤生长的氨基酸组合物、功能性食品及其应用
CN117159528A (zh) * 2023-01-13 2023-12-05 再造再生健康科技(杭州)有限公司 用于促进提高内源类胰岛素样生长因子1分泌的组合物
WO2025029650A1 (en) 2023-07-28 2025-02-06 Li Xiyan Nutritionally modified diets comprising aminoacids for use in treating a disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070270355A1 (en) * 2006-05-11 2007-11-22 Garcia Ramon D Sport drink containing amino acids and carbohydrates
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2009519942A (ja) * 2005-12-14 2009-05-21 アンブルックス，インコーポレイテッド 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用
JP2014512803A (ja) * 2011-02-23 2014-05-29 ムドスーレ エルティディ 個人的腫瘍プロファイリング治療のための組成物及び方法
US20140170259A1 (en) * 2012-12-14 2014-06-19 Mead Johnson Nutrition Company Nutritional composition for promoting satiety
US20170143025A1 (en) * 2014-07-01 2017-05-25 N.V. Nutricia Amino acid based diet with improved taste
JP2019507754A (ja) * 2016-02-23 2019-03-22 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 少なくとも２つの非必須アミノ酸を欠くダイエタリー製品

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832465A (en) * 1971-12-09 1974-08-27 H Ghadimi Injectable amino acid composition commensurate to the anabolic need of the body and method of using same
US4734401A (en) 1986-03-17 1988-03-29 W. R. Grace & Co. Process for spray drying amino acid compositions
US4988724A (en) 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
IT1289754B1 (it) * 1996-12-16 1998-10-16 Professional Dietetics Srl Composizioni a base di aminoacidi
US6713501B1 (en) 1998-03-13 2004-03-30 The Johns Hopkins University Supplement for dialysis patients
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
US20030129262A1 (en) 2001-08-30 2003-07-10 Epner Daniel E. Methionine restriction for cancer therapy
JP4836044B2 (ja) 2004-04-02 2011-12-14 味の素株式会社 経口アミノ酸ニキビ治療剤
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
US20060280840A1 (en) 2005-05-24 2006-12-14 Robertson Marion G Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system
WO2007056176A2 (en) 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
US20100151062A1 (en) 2008-12-16 2010-06-17 Bruno Stefanon Determining nutrients for animals through gene expression
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
BR112012009423A2 (pt) 2009-10-22 2017-06-13 Univ Southern California método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos
JP5760010B2 (ja) 2010-02-01 2015-08-05 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
CA2799431A1 (en) 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
CN103068381A (zh) 2010-08-11 2013-04-24 兴和株式会社 用于肝细胞癌的预防和／或治疗的医药
WO2012135714A2 (en) 2011-03-30 2012-10-04 Whitehead Institute For Biomedical Research Serine biosynthesis pathway inhibition for treatment of cancer
CN103184208B (zh) 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用
WO2014049566A2 (en) 2012-09-28 2014-04-03 Stellenbosch University Nutritional kit
WO2015003021A2 (en) * 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN106456723B (zh) 2014-04-29 2021-03-09 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
CA2976106A1 (en) 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
EP3352586A4 (en) 2015-09-21 2019-05-15 The Board Of Trustees Of The Leland Stanford Junior University NUTRITIONAL TREATMENT FOR CANCER DISEASES
JP7623784B2 (ja) 2016-10-13 2025-01-29 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
CA3119300A1 (en) 2017-11-13 2019-05-16 Cancer Research Technology Ltd. Dietary product
EP3723772A4 (en) 2017-12-11 2021-09-08 Filtricine, Inc. COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR THE TREATMENT OF CANCER AND METABOLIC INTERVENTION THERAPY
US20190177651A1 (en) 2017-12-12 2019-06-13 Afton Chemical Corporation Lubricant compositions comprising olefin copolymer dispersants in combination with additives
GB201807155D0 (en) * 2018-05-01 2018-06-13 Liverpool Womens Trust Nhs Found Trust Neonatal Parenteral nutrition formulations
WO2021016132A1 (en) * 2019-07-19 2021-01-28 Filtricine, Inc. Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses
JP2023530235A (ja) 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
EP4181914A2 (en) 2020-07-15 2023-05-24 The Trustees of Princeton University Ketogenic diet and ketone supplementation for cancer therapy
JP7727286B2 (ja) 2020-09-23 2025-08-21 アミノヴィタ エセ．エレ． 癌の代謝療法
JP2024504260A (ja) 2020-12-16 2024-01-31 フェイス セラピューティクス インコーポレイテッド セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法
WO2023130140A2 (en) 2022-01-03 2023-07-06 Faeth Therapeutics, Inc. Personalized methods of treating cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519942A (ja) * 2005-12-14 2009-05-21 アンブルックス，インコーポレイテッド 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用
US20070270355A1 (en) * 2006-05-11 2007-11-22 Garcia Ramon D Sport drink containing amino acids and carbohydrates
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2014512803A (ja) * 2011-02-23 2014-05-29 ムドスーレ エルティディ 個人的腫瘍プロファイリング治療のための組成物及び方法
US20140170259A1 (en) * 2012-12-14 2014-06-19 Mead Johnson Nutrition Company Nutritional composition for promoting satiety
US20170143025A1 (en) * 2014-07-01 2017-05-25 N.V. Nutricia Amino acid based diet with improved taste
JP2019507754A (ja) * 2016-02-23 2019-03-22 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 少なくとも２つの非必須アミノ酸を欠くダイエタリー製品

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE FEBS JOURNAL, vol. 284, JPN6025022966, 2017, pages 1726 - 1737, ISSN: 0005612331 *

Also Published As

Publication number Publication date
CA3181158A1 (en) 2021-12-09
US20250367169A1 (en) 2025-12-04
AU2021283293A1 (en) 2023-01-19
CN116075238B (zh) 2025-11-04
CN116075238A (zh) 2023-05-05
AU2021283293B2 (en) 2025-06-26
US12220402B2 (en) 2025-02-11
WO2021247724A1 (en) 2021-12-09
EP4161501A1 (en) 2023-04-12
CN121445725A (zh) 2026-02-03
US20220117943A1 (en) 2022-04-21
EP4161501A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
US12220402B2 (en) Formulations for personalized methods of treatment
CN100355420C (zh) 富含亮氨酸的营养组合物
EP2705844A1 (en) Nutritional composition
KR102917056B1 (ko) 대사증후군 개선용 식품 보충제 및 조성물
US11419915B2 (en) Compositions and methods for the treatment of malnutrition
BR112013033127B1 (pt) suplemento alimentar, uso do suplemento alimentar, e composição alimentar
JP2019108364A (ja) 栄養組成物
WO2018085440A1 (en) Reduction and prevention of muscle loss by conjugated linoleic acid (cla) and vitamin d
US20160029683A1 (en) Low calorie infant formula containing beta-hydroxy-beta-methylbutyric acid
WO2021173950A1 (en) Sweetener and manufacturing process therefor
Challem Context and Applications
HK1194671A (en) Nutritional composition
HK1108563B (zh) 富含亮氨酸的营养组合物
TW201713320A (zh) 茄紅素（ｌｙｃｏｐｅｎｅ）之新用途及基於此新用途之製劑
ZA200501922B (en) Leucine-enriched nutritional compositions.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260415